Open Label, Dose Escalation, Followed by Open Label, Single Arm, Multi-Center Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients With Mycosis Fungoides Type CTCL (Stage IB-IVB) or Sezary Syndrome Who Are Refractory or Intolerant to Targretin (Bexarotene) and One Other Standard Therapy.

Trial Profile

Open Label, Dose Escalation, Followed by Open Label, Single Arm, Multi-Center Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients With Mycosis Fungoides Type CTCL (Stage IB-IVB) or Sezary Syndrome Who Are Refractory or Intolerant to Targretin (Bexarotene) and One Other Standard Therapy.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2012

At a glance

  • Drugs Zanolimumab (Primary)
  • Indications Mycosis fungoides; Sezary syndrome
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 25 Jul 2012 Planned end date changed from 1 Feb 2011 to 1 Feb 2014 as reported by ClinicalTrials.gov.
    • 25 Jul 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 07 Sep 2010 Final data collection is expected in early 2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top